// App-Quantinova.ai

2513 : Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).

Researchers

Presenter

  • Caroline Ogilvie Michie

Principal Investigators

  • Shahneen Kaur Sandhu

  • William R. Schelman

  • Robert Michael Wenham

  • L Rhoda Molife

  • George Wilding

  • Aurelius Gabriel Omlin

  • Vikram Kansra

  • David G. Brooks

  • Robert E. Martell

  • Stanley B. Kaye

  • Johann Sebastian De Bono

Medical Centers

  • Division of Hematology/Oncology Tufts Medical Center, Boston, MA

  • TESARO, Inc., Waltham, MA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • High grade serous ovarian cancer

  • Prostate cancer

  • Gynaecological cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Phosphatase and tensin homolog

  • Circulating tumor cells

Drug/Treatment

  • Niraparib

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT0074902

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved